JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They ...

Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.

H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...

JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...

JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion (ESPR – Research Report), with ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...

Bempedoic acid is under clinical development by Esperion Therapeutics and currently in Phase II for Hypercholesterolemia. According to GlobalData, Phase II drugs for Hypercholesterolemia have a 57% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...